Clinical Trial Update: Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating trilaciclib in Chinese patients with extensive-stage small cell lung cancer for chemotherapy-induced myelosuppression, antitumor effect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• trilaciclib (trilaciclib)

Snippet

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Conditions: Extensive-stage Small-cell Lung Cancer | Phase 4 | Status: COMPLETED